BRAF and cancer: identified BRAFV600E mutations in established cancer cell lines DBTRG-05MG and AM38 (6), which subsequently became workhorses for preclinical testing, in particular of small molecule BRAF inhibitors, including PLX4720, a tool compound of Vemurafenib (Table 1).